European Medicines Agency validates Pierre Fabre Laboratories’ marketing authorisation application for combination BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) for patients with BRAFV600-mutant advanced non-small cell lung cancer (NSC ...Middle East

– BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) shows meaningful clinical benefit in adult patients with BRAFV600-mutant advanced NSCLC – The application is based on results from the PHAROS study,[1] which showed an objective response rate of 75% in treatment-naïve patients and 46% in previously treated patients – If approved, the new indication for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) will be a potential new treatment option for adult patients with BRAFV600-mutant advanced NSCLC CASTRES, France, Nov. 2, 2023 /PRNewswire/ — Intended for international media only / not intended for UK- and US-based media Pierre Fabre Laboratories announced today that the European Medicines Age

Hence then, the article about european medicines agency validates pierre fabre laboratories marketing authorisation application for combination braftovi encorafenib and mektovi binimetinib for patients with brafv600 mutant advanced non small cell lung cancer nsc was published today ( Thursday 02/11/2023 - 02:17 PM ) and is available on TOP world News today ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( European Medicines Agency validates Pierre Fabre Laboratories’ marketing authorisation application for combination BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) for patients with BRAFV600-mutant advanced non-small cell lung cancer (NSC )

Also on site :

• Saudi Arabia to unify LPG gas cylinder prices nationwide from January 2026
• Two dozen killed in Ukrainian strike on Russian New Year’s celebration – governor
• Volunteer in Iran’s Revolutionary Guard reportedly killed during widening protests